What it's for (Indications)
- Trandolapril, an angiotensin-converting enzyme (ACE) inhibitor, is clinically indicated for the management and treatment of several cardiovascular conditions.
- Its primary use is in the treatment of essential hypertension, either as monotherapy or in combination with other antihypertensive agents, to effectively lower elevated blood pressure and reduce the risk of associated cardiovascular events such as stroke and myocardial infarction.
- Beyond hypertension, trandolapril is also indicated for the treatment of left ventricular dysfunction following a myocardial infarction (MI) in clinically stable patients, where it has been shown to improve survival and reduce the incidence of severe heart failure.
- Furthermore, it is prescribed for patients with symptomatic heart failure (New York Heart Association Class II-IV) to reduce mortality and morbidity, often used in conjunction with diuretics and digoxin.
- Its renoprotective effects may also be beneficial in patients with specific forms of renal disease, particularly those with microalbuminuria, although this is a class effect and typically considered within the broader context of ACE inhibitor therapy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of trandolapril must be individualized based on the patient's clinical response and tolerability, typically administered once daily. For the treatment of essential hypertension, the usual starting dose is 1 mg once daily for non-elderly patients with normal renal function, with a common maintenance dose ranging from 2 mg to 4 mg once daily. Doses may be titrated up to a maximum of 8 mg daily. In patients with stable left ventricular dysfunction post-myocardial infarction, treatment typically begins with 0.5 mg once daily, gradually increasing to a target dose of 4 mg once daily as tolerated. For patients with heart failure, the initial dose is 0.5 mg once daily, titrated slowly upwards to a maintenance dose of 2 mg to 4 mg once daily. Dosage adjustments are crucial in patients with renal impairment (creatinine clearance less than 30 mL/min), where a lower initial dose of 0.5 mg once daily is recommended, and the maximum dose should not exceed 2 mg daily. Careful monitoring of blood pressure, renal function, and serum potassium is essential during dose initiation and titration. |
Safety & Warnings
Common Side Effects
- Trandolapril, like other ACE inhibitors, is associated with a range of potential side effects, although many patients tolerate the medication well.
- Common side effects include a persistent, dry, non-productive cough, which is often dose-dependent and reversible upon discontinuation.
- Other frequently reported adverse events include dizziness, fatigue, and headache, particularly during the initial phases of treatment due to blood pressure reduction.
- Hypotension, especially orthostatic hypotension, can occur, particularly in volume-depleted patients or those concomitantly receiving diuretics.
- More serious, albeit less common, side effects include angioedema, a potentially life-threatening swelling of the face, lips, tongue, and larynx, which requires immediate medical attention.
- Hyperkalemia (elevated serum potassium levels) is a risk, especially in patients with renal impairment, diabetes, or those taking potassium-sparing diuretics or potassium supplements.
- Renal dysfunction, including acute renal failure, can also occur, particularly in patients with pre-existing renal disease or bilateral renal artery stenosis.
- Other adverse effects may include rash, taste disturbance (dysgeusia), nausea, diarrhea, and rarely, hepatic dysfunction.
Serious Warnings
- Black Box Warning: WARNING: FETAL TOXICITY. When pregnancy is detected, discontinue trandolapril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
- Trandolapril carries several important warnings and contraindications that healthcare professionals must consider to ensure patient safety.
- It is absolutely contraindicated in pregnant women, particularly during the second and third trimesters, due to the significant risk of fetal injury and death (fetotoxicity, neonatal anuria, hypoplasia of lung, skeletal deformities).
- Women of childbearing potential should be adequately counseled.
- It is also contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment or hereditary/idiopathic angioedema.
- Co-administration with sacubitril/valsartan (Entresto) is contraindicated due to an increased risk of angioedema, requiring a 36-hour washout period between treatments.
- Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with an ACE inhibitor, an angiotensin receptor blocker (ARB), or aliskiren is generally not recommended due to increased risks of hypotension, hyperkalemia, and renal impairment.
- Caution is advised in patients with severe aortic stenosis or hypertrophic obstructive cardiomyopathy, as it may exacerbate obstruction.
- Patients with pre-existing renal impairment, renovascular hypertension (e.
- g.
- , bilateral renal artery stenosis), or those on diuretic therapy require careful monitoring of renal function and serum potassium, as they are at increased risk of hyperkalemia and acute renal failure.
- Hypotension can be severe, especially after the first dose, in volume-depleted or salt-depleted patients.
How it Works (Mechanism of Action)
Trandolapril is a prodrug that is rapidly and extensively hydrolyzed in the liver to its active metabolite, trandolaprilat. Trandolaprilat is a potent, competitive inhibitor of the angiotensin-converting enzyme (ACE), an enzyme primarily responsible for converting inactive angiotensin I into the powerful vasoconstrictor angiotensin II. By inhibiting ACE, trandolaprilat effectively reduces the systemic levels of angiotensin II. This reduction leads to several beneficial physiological effects: 1) Decreased vasoconstriction, resulting in peripheral vasodilation and a reduction in systemic vascular resistance, thereby lowering blood pressure. 2) Reduced secretion of aldosterone, a hormone that promotes sodium and water retention and potassium excretion; consequently, sodium and water excretion are increased, and potassium retention occurs. 3) Inhibition of bradykinin degradation. Bradykinin is a potent vasodilator, and its increased levels contribute to the hypotensive effect. The overall result is a reduction in both preload and afterload on the heart, leading to improved cardiac efficiency and reduced myocardial workload. This mechanism underlies its efficacy in hypertension, heart failure, and post-myocardial infarction settings, contributing to improved cardiovascular outcomes and cardiac remodeling.
Commercial Brands (Alternatives)
No other brands found for this formula.